Oncology Reviews最新文献_第8页

Perceived factors to providing palliative care for patients with cancer - a qualitative systematic review. 为癌症患者提供姑息治疗的感知因素-一项定性系统综述。

IF 3.6

Oncology Reviews Pub Date : 2020-05-19 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.463

Haydeh Heidari, Marjan Mardani-Hamooleh, Masoud Amiri

{"title":"Perceived factors to providing palliative care for patients with cancer - a qualitative systematic review.","authors":"Haydeh Heidari, Marjan Mardani-Hamooleh, Masoud Amiri","doi":"10.4081/oncol.2020.463","DOIUrl":"https://doi.org/10.4081/oncol.2020.463","url":null,"abstract":"Palliative care (PC) is one of the necessary cares given throughout a patient's experience with cancer. The aim of this study was to identify the perceived factors to providing PC for patients with cancer. Our study was a systematic review of qualitative literature. To this end, electronic databases, including CINAHL, PubMed, PsycINFO, Ovid, and Web of Science as well as Persian databases were searched and qualitative studies on the role of PC in patients with cancer published between Jan 2008 and Dec 2017 were selected. Generally, 12 studies were reviewed. A thematic synthesis approach was used to analyze the data. Exploring the selected articles, the findings on the perceived factors to providing PC for patients with cancer were categorized into three themes, including organizational factors, ethical factors, and psychological factors. This qualitative systematic review expands our knowledge about factors influencing the provision of PC for patients with cancer. It is necessary for health system managers and caregivers to pay attention to all aforesaid factors in order to improve PC for cancer patients.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"463"},"PeriodicalIF":3.6,"publicationDate":"2020-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/a0/onco-14-1-463.PMC7246343.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37995673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of cytotoxic chemotherapy-induced hand-foot syndrome. 细胞毒性化疗所致手足综合征的处理。

IF 3.6

Oncology Reviews Pub Date : 2020-05-13 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.442

Johannes J M Kwakman, Yannick S Elshot, Cornelis J A Punt, Miriam Koopman

{"title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome.","authors":"Johannes J M Kwakman, Yannick S Elshot, Cornelis J A Punt, Miriam Koopman","doi":"10.4081/oncol.2020.442","DOIUrl":"https://doi.org/10.4081/oncol.2020.442","url":null,"abstract":"Improvements in systemic cancer treatments have resulted in more patients surviving for prolonged periods of time on treatment. This has made treatment-related toxicity and quality of life concerns increasingly relevant. Hand-foot syndrome (HFS) is a common skin reaction to systemic therapy that should be anticipated with chemotherapeutic treatments such as pegylated liposomal doxorubicin, docetaxel, and fluoropyrimidines. In this review we discuss current knowledge of the diagnosis, incidence, pathogenesis, and management of hand-foot syndrome (HFS). Although HFS is not life threatening, it can cause significant discomfort and impairment of function, especially in elderly patients, and may seriously impact quality of life. The incidence of HFS is dependent on the chemotherapeutic drug used, the treatment schedule, and the median duration of treatment. Effective measures for prevention and treatment of HFS include systemic and topical treatments, dose reductions, and switching to other drugs in the same class that are associated with lower rates of HFS. These approaches allow patients to continue cancer treatment while reducing negative impacts on quality of life. Awareness and early recognition are important to ensure timely treatment and avoidance of dose reductions or treatment discontinuation. We provide useful recommendations to guide the management of HFS in clinical practice.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"442"},"PeriodicalIF":3.6,"publicationDate":"2020-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.442","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37957424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review. 前列腺特异性抗原速度在前列腺癌诊断和预后中的系统评价。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.449

Arslaan Javaeed, Sanniya Khan Ghauri, Abdellatif Ibrahim, Mohamed Fahmy Doheim

引用次数: 4

Elucidating the pathogenic and biomarker potentials of FOXG1 in glioblastoma. 阐明FOXG1在胶质母细胞瘤中的致病和生物标志物潜力。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.444

Seidu A Richard, Zhou Jia-Hao

{"title":"Elucidating the pathogenic and biomarker potentials of FOXG1 in glioblastoma.","authors":"Seidu A Richard, Zhou Jia-Hao","doi":"10.4081/oncol.2020.444","DOIUrl":"https://doi.org/10.4081/oncol.2020.444","url":null,"abstract":"Glioblastoma (GB) is an extremely pugnacious brain cancer originating from neural stem (NS) cell-like cells. Forkhead box G1 (FOXG1; previously recognized as BF-1, qin, Chicken Brain Factor 1, or XBF-1 and renamed FOXG1 for mouse and human, and FoxG1 for other chordates) is an evolutionary preserved transcription factor driven from the forkhead box group of proteins FOXG1 modulates the speed of neurogenesis by maintaining progenitor cells in a proliferative mode as well as obstructing their differentiation into neurons during the initial periods of cortical formation. FOXG1 has been implicated in the formation of central nervous system (CNS) tumors and precisely GBs. Pathophysiologically, joint actions of FOXG1 and phosphatidylinositol- 3-kinases (PI3K) intermediate in intrinsic resistance of human GB cells to transforming growth factor-beta (TGF-β) stimulation of cyclin-dependent kinase inhibitor 1(p21Cip1) as well as growth inhibition. FOXG1 and NOTCH signaling pathways may functionally interrelate at different stages to facilitate gliomagenesis. Furthermore, FoxG1 actively contributed to the formation of transcription suppression complexes with corepressors of the Groucho/transducin-like Enhancer of split (Gro/TLEs). Also, FOXG1 was stimulated by Gro/TLE1 and abridged by Grg6. FOXG1 silencing in brain tumor-initiating cells (BTICs) also resulted in diminished secretion of markers characteristic undifferentiated natural neural stem/progenitor cells (NSPC) states, such as Oligodendrocyte transcription factor (OLIG2), (sex determining region Y)-box 2. (SOX2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI1). This review therefore focuses on the pathogenic and biomarker potentials of FOXG1 in GB.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"444"},"PeriodicalIF":3.6,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37923419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

EPAC2: A new and promising protein for glioma pathogenesis and therapy. EPAC2:神经胶质瘤发病机制和治疗的新蛋白。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.446

Seidu A Richard

{"title":"EPAC2: A new and promising protein for glioma pathogenesis and therapy.","authors":"Seidu A Richard","doi":"10.4081/oncol.2020.446","DOIUrl":"https://doi.org/10.4081/oncol.2020.446","url":null,"abstract":"Gliomas are prime brain cancers which are initiated by malignant modification of neural stem cells, progenitor cells and differentiated glial cells such as astrocyte, oligodendrocyte as well as ependymal cells. Exchange proteins directly activated by cAMP (EPACs) are crucial cyclic adenosine 3',5'-monophosphate (cAMP)-determined signaling pathways. Cyclic AMP-intermediated signaling events were utilized to transduce protein kinase A (PKA) leading to the detection of EPACs or cAMP-guanine exchange factors (cAMP-GEFs). EPACs have been detected as crucial proteins associated with the pathogenesis of neurological disorders as well as numerous human diseases. EPAC proteins have two isoforms. These isoforms are EPAC1 and EPAC2. EPAC2 also known as Rap guanine nucleotide exchange factor 4 (RAPGEF4) is generally expression in all neurites. Higher EAPC2 levels was detected in the cortex, hippocampus as well as striatum of adult mouse brain. Activation as well as over-secretion of EPAC2 triggers apoptosis in neurons and EPAC-triggered apoptosis was intermediated via the modulation of Bcl-2 interacting member protein (BIM). EPAC2 secretory levels has proven to be more in low-grade clinical glioma than high-grade clinical glioma. This review therefore explores the effects of EPAC2/RAPGEF4 on the pathogenesis of glioma instead of EPAC1 because EPAC2 and not EPAC1 is predominately expressed in the brain. Therefore, EPAC2 is most likely to modulate glioma pathogenesis rather than EPAC1.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"446"},"PeriodicalIF":3.6,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.446","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37923332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Periocular basal cell carcinoma - clinical perspectives. 眼周基底细胞癌的临床观点。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.420

Alena Furdova, Karolina Kapitanova, Alexandra Kollarova, Juraj Sekac

引用次数: 16

RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane. 摘要:羊膜抗癌特性的生物学机制。

IF 3.6

Oncology Reviews Pub Date : 2020-04-27 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.493

Camillo Porta

{"title":"RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane.","authors":"Camillo Porta","doi":"10.4081/oncol.2020.493","DOIUrl":"https://doi.org/10.4081/oncol.2020.493","url":null,"abstract":"To our readers: \u0000With deep regrets, we inform our Readers that the article The biological mechanism involved in anticancer properties of amniotic membrane (DOI: https://doi.org/10.4081/oncol.2020.429), which has been published in the current issue of Oncology Reviews (2020-1), contains verbatim text plagiarized from another paper.1 The manuscript must be considered as retracted. On behalf of the Editorial Board of Oncology Reviews, I apologize to the Author of the manuscript whose text was plagiarized by Ameneh Jafari, Hassan Niknejad, Mostafa Rezaei-Tavirani, Caitlin D’Amico, Hakimeh Zali that this was not picked up in the peer review process. I also apologize to the affected journal for the violation of copyright due to plagiarism. Unfortunately we were not able to detect it before publication due to the language of the original paper (Slovenian). Oncology Reviews is uncompromising in its commitment to scientific integrity. When credible evidence of misconduct is brought to our attention, our commitment to the scientific record and to our readership requires immediate notification. Oncology Reviews is increasingly employing sophisticated software to detect plagiarism. Other journals use similar tools. Authors should be aware that most journals routinely employ plagiarism detection software, and that any plagiarism is likely to be detected. \u0000Camillo Porta, Editor-in-Chief Oncology Reviews \u0000 \u0000Reference1. Ramuta TZ, Cirman T, Erdani Kreft M. Celicno-bioloski mehanizmi delovanja amnijske membrane proti raku in možnosti za njeno uporabo pri zdravljenju raka [Cell-biological mechanisms of amniotic membrane anticancer activity and the possibilities of its use in anticancer therapy]. Slovenian Medical Journal (Zdravniski vestnik) 2018;87(9-10):483-92. (DOI: 10.6016/ZdravVestn.2674).","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"493"},"PeriodicalIF":3.6,"publicationDate":"2020-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.493","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37921624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Periodontitis and oral cancer - current concepts of the etiopathogenesis. 牙周炎和口腔癌--目前的发病机制概念。

IF 3.6

Oncology Reviews Pub Date : 2020-03-18 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.465

Soussan Irani, Iman Barati, Mohammadreza Badiei

引用次数: 0

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review. 替莫唑胺延长辅助治疗对新诊断的多形性胶质母细胞瘤的影响:荟萃分析和系统评价。

IF 3.6

Oncology Reviews Pub Date : 2020-02-18 DOI: 10.4081/oncol.2020.461

Ehsan Alimohammadi, Seyed Reza Bagheri, Shahram Taheri, Maliheh Dayani, Alireza Abdi

{"title":"The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review.","authors":"Ehsan Alimohammadi, Seyed Reza Bagheri, Shahram Taheri, Maliheh Dayani, Alireza Abdi","doi":"10.4081/oncol.2020.461","DOIUrl":"https://doi.org/10.4081/oncol.2020.461","url":null,"abstract":"Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy is the current standard treatment for glioblastoma multiforme (GBM). The present metaanalysis investigated the impact of prolonged TMZ maintenance therapy (more than 6 cycles) in comparison with standard TMZ maintenance therapy (exactly six cycles) on overall survival (OS) and progression-free survival (PFS) of patients with GBM. A meta-analysis of the literature was conducted using Medline, PubMed, EMBASE and the Cochrane Library in accordance with PRISMA guidelines. Seven articles involving 1018 patients were included. The overall survival was higher in the case group (>6 cycles TMZ) compared to the control group (6 cycles TMZ) (Z=2.375, P=0.018). The lower and upper limits were between 1.002-10.467 months. The case group had higher progression-free survival compared with the control group (Z=3.84; P<0.001). The lower and upper limits were between 2.559-7.894 months. Evidence from this meta-analysis suggests that prolonged TMZ therapy compared to the standard 6-cycle TMZ therapy was associated with higher survival in patients with glioblastoma.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"461"},"PeriodicalIF":3.6,"publicationDate":"2020-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37721399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

The biological mechanism involved in anticancer properties of amniotic membrane. 羊膜抗癌特性的生物学机制。

IF 3.6

Oncology Reviews Pub Date : 2020-02-18 DOI: 10.4081/oncol.2020.429

Ameneh Jafari, Hassan Niknejad, Mostafa Rezaei-Tavirani, Hakimeh Zali

引用次数: 4